Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral topotecan in cancer patients with impaired renal function
NL-OMON30871Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of topotecan in Nonhematologic neoplasms (5 arms), sponsored by GSK. Primary endpoints: Adverse events and Laboratory value changes. Started Oct 2007; status: active, not recruiting.
02
Drugs
topotecan
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON30871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30871.